Nano-vectors for CRISPR/Cas9-Mediated Genome Editing.

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• The CRISPR/Cas9 system offers revolutionary potential for genetic diseases and cancer therapy.
• Efficient and safe in vivo delivery of CRISPR/Cas9 remains a critical challenge.
• Non-viral nanovectors present advantages over viral vectors, including cost-effectiveness and lower immunogenicity.

Purpose of the Study:

• To review recent advances in CRISPR/Cas9 genome editing system delivery using non-viral nanovectors.
• To highlight therapeutic applications for cancers and genetic diseases.
• To discuss challenges and future strategies for nanovector-mediated CRISPR/Cas9 delivery.

Main Methods:

• Review of literature on nanovector-based delivery of CRISPR/Cas9 components (DNA plasmid, mRNA, ribonucleoprotein).
• Analysis of lipid-based, polymer-based, and polymer-inorganic nanovectors.
• Examination of gene-editing pathways: non-homologous end joining and homology-directed repair.

Main Results:

• Nanovectors demonstrate potential for delivering CRISPR/Cas9 cargoes for cancer and genetic disease treatment.
• Various nanovector types show promise in protecting CRISPR/Cas9 from degradation and enabling efficient delivery.
• Progress has been made in utilizing different CRISPR/Cas9 formats (DNA, mRNA, RNP) with nanovectors.

Conclusions:

• Non-viral nanovectors are a promising strategy for in vivo CRISPR/Cas9 delivery.
• Further development is needed to overcome challenges in nanovector design and clinical translation.
• Optimized nanovector systems could significantly advance CRISPR/Cas9-based therapeutics.